BIOCON GROUP

FACT SHEET

September - 2021

BIOCON LIMITED (CONSOLIDATED) PROFIT & LOSS STATEMENT			(Rs. Crores
Particulars	Q2'FY 22	Q2'FY 21	Variance %
INCOME			
Generics	530	604	-12%
Biosimilars	743	676	10%
Novel Biologics	12	-	
Research services	610	520	17%
Inter-segment	(54)	(50)	9%
Revenue from operations #	1,840	1,750	5%
Other income	105	16	577%
TOTAL REVENUE	1,945	1,765	10%
EXPENDITURE			
Material & Power costs	641	606	6%
Staff costs	437	383	14%
Research & Development expenses*	146	148	-1%
Other expenses	170	222	-23%
Manufacturing, staff & other expenses	1,395	1,358	3%
EBITDA	551	407	35%
Interest & Finance charges	23	7	246%
Depreciation & Amortisation	202	178	13%
Share of loss / (profit) in JV / Associate, net	51	5	100%
PBT BEFORE EXCEPTIONAL ITEM	276	218	27%
Exceptional item	(70)	-	-
PBT	206	218	-5%
Taxes	59	22	163%
Taxes on exceptional item	(12)	_	0%
NET PROFIT BEFORE MINORITY INTEREST	160	195	-18%
Minority interest	29	26	13%
Minority interest on exceptional item	(8)	_	
NET PROFIT FOR THE PERIOD	138	169	-18%
EPS Rs.	1.2	1.4	
NET PROFIT BEFORE EXCEPTIONAL ITEM	188	169	11%
		109	
Exceptional item, net of taxes	(50)	-	0%
NET PROFIT FOR THE PERIOD	138	169	-18%
# Licensing Income	13	10	
* Gross Research & Development expenses	165	165	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q2' FY 22	Q1' FY 22	Variance %
INCOME			
Generics	530	486	9%
Biosimilars	743	758	-2%
Novel Biologics	12	11	-
Research services	610	595	3%
Inter-segment	(54)	(89)	-39%
Revenue from operations #	1,840	1,761	5%
Other income	105	47	122%
TOTAL REVENUE	1,945	1,808	8%
EXPENDITURE			
Material & Power costs	641	686	-7%
Staff costs	437	395	11%
Research & Development expenses*	146	120	22%
Other expenses	170	171	0%
Manufacturing, staff & other expenses	1,395	1,371	2%
EBITDA	551	437	26%
Interest & Finance charges	23	20	13%
Depreciation & Amortisation	202	195	3%
Share of loss / (profit) in JV / Associate, net	51	56	100%
PBT BEFORE EXCEPTIONAL ITEM	276	166	67%
Exceptional item	(70)	-	-
PBT	206	166	24%
Taxes	59	57	2%
Taxes on exceptional item	(12)	-	0%
NET PROFIT BEFORE MINORITY INTEREST	160	108	47%
Minority interest	29	24	23%
Minority interest on exceptional item	(8)	-	-
NET PROFIT FOR THE PERIOD	138	84	64%
EPS Rs.	1.2	0.7	
NET PROFIT BEFORE EXCEPTIONAL ITEM	188	84	123%
Exceptional item, net of taxes	(50)	-	
NET PROFIT FOR THE PERIOD	138	84	64%
# Licensing Income	13	10	
* Gross Research & Development expenses	165	136	

Particulars H1' FY 22 H1' FY 21 Variance % INCOME Generics 1,016 1,225 -17% Biosimilars 1,501 1,368 10% Novel Biologics 23 - - Research services 1,205 941 28% Inter-segment (144) (91) 59% Revenue from operations # 3,601 3,444 5% Other income 152 34 350% TOTAL REVENUE 3,753 3,477 8% EXPENDITURE Material & Power costs 1,327 1,229 8% Costs 832 742 12% Manufacturing, staff & other expenses 2,766 2,639 5% Depreciation & Amortisation 396 345 15% Share of loss / (profit) in IV / Associate, net 107 9 100% PBT BEFORE EXCEPTIONAL ITEM 442 466 -5% EXERDIDITIONE 33 45 20% Depreciation & Amortisation 396 <t< th=""><th>BIOCON LIMITED (CONSOLIDATED)</th><th></th><th></th><th></th></t<>	BIOCON LIMITED (CONSOLIDATED)			
INCOME Generics Incl Incl Incl Incl Generics 1,016 1,225 -17% Biosimilars 1,501 1,368 10% Novel Biologics 23 - - Research services 1,205 941 28% Inter-segment (144) (91) 59% Revenue from operations # 3,601 3,444 5% Other income 152 34 350% TOTAL REVENUE 3,753 3,477 8% EXPENDITURE 3,753 3,477 8% Material & Power costs 1,327 1,229 8% Staff costs 832 742 12% Manufacturing, staff & other expenses 2,766 2,639 5% Other expenses 42 19 123% Depreciation & Amortisation 396 345 15% Share of loss / (profit) in JV / Associate, net 107 9 100% PBT BEFORE EXCEPTIONAL ITEM 272 466	PROFIT & LOSS STATEMENT			(Rs. Crores)
Generics 1,016 1,225 -17% Biosimilars 1,501 1,368 10% Novel Biologics 23 - - Research services 1,205 941 28% Inter-segment (144) (91) 59% Revenue from operations # 3,601 3,444 59% Other income 152 34 350% TOTAL REVENUE 3,753 3,477 8% EXPENDITURE 3,753 3,477 8% Material & Power costs 1,327 1,229 8% Staff costs 832 742 12% Research & Development expenses* 266 255 4% Other expenses 2,766 2,639 5% Depreciation & Amortisation 396 345 15% Share of loss / (profit) in JV / Associate, net 107 9 100% PBT BEFORE EXCEPTIONAL ITEM 442 466 -5% Exceptional item (70) - -	Particulars	H1' FY 22	H1' FY 21	Variance %
Biosimilars 1,501 1,368 10% Novel Biologics 23 - - Research services 1,205 941 28% Inter-segment (144) (91) 59% Revenue from operations # 3,601 3,444 5% Other income 152 34 350% TOTAL REVENUE 3,753 3,477 8% Material & Power costs 1,327 1,229 8% Staff costs 1,327 1,229 8% Research & Development expenses* 266 255 4% Other expenses 342 413 -17% Manufacturing, staff & other expenses 2,766 2,639 5% EITDA 987 839 18% Interest & Finance charges 42 19 123% Depreciation & Amortisation 396 345 15% BITDA 372 466 -5% Exceptional item (70) - - PBT 372 466 -20% Taxes on exceptional item <t< td=""><td>INCOME</td><td></td><td></td><td></td></t<>	INCOME			
Novel Biologics 23 - - Research services 1,205 941 28% Inter-segment (144) (91) 59% Revenue from operations # 3,601 3,444 5% Other income 3,753 3,477 8% EXPENDITURE 3,753 3,477 8% Material & Power costs 1,327 1,229 8% Staff costs 832 742 12% Research & Development expenses* 266 2,55 4% Other expenses 342 413 -17% Manufacturing, staff & other expenses 2,766 2,639 5% ENTDA 987 839 18% Interest & Finance charges 2,766 2,639 5% Depreciation & Amortisation 396 345 113% Share of loss / (profit) in JV / Associate, net 107 9 100% PBT 372 466 -20% Taxes 116 103 12%	Generics	1,016	1,225	-17%
Research services 1,205 941 28% Inter-segment (144) (91) 59% Revenue from operations # 3,601 3,444 5% Other income 152 34 350% TOTAL REVENUE 3,753 3,477 8% EXPENDITURE 3,753 3,477 8% Material & Power costs 1,327 1,229 8% Staff costs 832 742 12% Research & Development expenses* 266 2,55 4% Other expenses 342 413 -17% Manufacturing, staff & other expenses 2,766 2,639 5% EBITDA 987 839 18% Interest & Finance charges 42 19 123% Depreciation & Amortisation 396 345 15% Share of loss / (proft) in JV / Associate, net 107 9 100% PBT BEFORE EXCEPTIONAL ITEM 442 466 -20% Taxes on exceptional item (12) <td< td=""><td>Biosimilars</td><td>1,501</td><td>1,368</td><td>10%</td></td<>	Biosimilars	1,501	1,368	10%
Inter-segment (144) (91) 59% Revenue from operations # 3,601 3,444 5% Other income 152 34 350% TOTAL REVENUE 3,753 3,477 8% EXPENDITURE 3,753 3,477 8% Material & Power costs 1,327 1,229 8% Staff costs 832 742 12% Research & Development expenses* 266 255 4% Other expenses 342 413 -17% Mandracturing, staff & other expenses 2,766 2,639 5% EBITDA 987 839 18% Interest & Finance charges 42 19 123% Depreciation & Amortisation 396 345 15% Share of loss / (profit) in JV / Associate, net 107 9 100% PBT BEFORE EXCEPTIONAL ITEM 442 466 -5% Kaces on exceptional item (f2) - 0% NET PROFIT BEFORE MINORITY INTEREST 268	Novel Biologics	23	-	-
Revenue from operations # 3,601 3,444 5% Other income 152 34 350% TOTAL REVENUE 3,753 3,477 8% EXPENDITURE 3,753 3,477 8% Material & Power costs 1,327 1,229 8% Staff costs 832 742 12% Research & Development expenses* 266 255 4% Other expenses 342 413 -17% Manufacturing, staff & other expenses 2,766 2,639 5% EBIDA 987 839 18% Interest & Finance charges 42 19 123% Depreciation & Amortisation 396 345 15% Share of loss / (profit) in JV / Associate, net 107 9 100% PBT 372 466 -20% Taxes on exceptional item (12) - 0% NET PROFIT BEFORE MINORITY INTEREST 268 363 -265% Minority interest 53 45	Research services	1,205	941	28%
Other income 152 34 350% TOTAL REVENUE 3,753 3,477 8% EXPENDITURE 3,753 3,477 8% Material & Power costs 1,327 1,229 8% Staff costs 832 742 12% Research & Development expenses* 266 255 4% Other expenses 3,766 2,639 5% BelTDA 987 839 18% Interest & Finance charges 42 19 123% Depreciation & Amortisation 396 345 15% Share of loss / (profit) in V / Associate, net 107 9 100% PBT 722 466 -20% Taxes on exceptional item (12) - 0% NET PROFIT BEFORE MINORITY INTEREST 268 363 - - NET PROFIT BEFORE EXCEPTIONAL ITEM 273 319 -30% PS Rs. 1.9 2.7 - - PBT 200 -	Inter-segment	(144)	(91)	59%
TOTAL REVENUE 3,753 3,477 8% EXPENDITURE Material & Power costs 1,327 1,229 8% Material & Power costs 832 742 12% Research & Development expenses* 266 255 4% Other expenses 342 413 -17% Manufacturing, staff & other expenses 2,766 2,639 5% EBITDA 987 839 18% Interest & Finance charges 42 19 123% Depreciation & Amortisation 396 345 15% Share of loss / (profit) in JV / Associate, net 107 9 100% PBT 372 466 -5% Exceptional item (70) - - BT 372 466 -20% Taxes on exceptional item (12) - 0% Minority interest 53 45 20% Minority interest on exceptional item (8) - - NET PROFIT BEFORE EXCEPTIONAL ITEM 223	Revenue from operations #	3,601	3,444	5%
EXPENDITURE 1,327 1,229 8% Material & Power costs 1,327 1,229 8% Staff costs 832 742 12% Research & Development expenses* 266 255 4% Other expenses 342 413 -17% Manufacturing, staff & other expenses 2,766 2,639 5% EBIDA 987 839 18% Interest & Finance charges 42 19 123% Depreciation & Amortisation 396 345 15% Share of loss / (profit) in JV / Associate, net 107 9 100% PBT BEFORE EXCEPTIONAL ITEM 442 466 -5% Exceptional item (70) - - PBT BEFORE EXCEPTIONAL ITEM 372 466 -20% Taxes 116 103 12% Minority interest 53 45 20% Minority interest 53 45 20% Minority interest on exceptional item (8) - <td>Other income</td> <td>152</td> <td>34</td> <td>350%</td>	Other income	152	34	350%
Material & Power costs 1,327 1,229 8% Staff costs 832 742 12% Research & Development expenses* 266 255 4% Other expenses 342 413 -17% Manufacturing, staff & other expenses 2,766 2,639 5% EBITDA 987 839 18% Interest & Finance charges 42 19 123% Depreciation & Amortisation 396 345 15% Share of loss / (profit) in JV / Associate, net 107 9 100% PBT EFORE EXCEPTIONAL ITEM 442 466 -5% Exceptional item (70) - - - PBT 372 466 -20% - Taxes on exceptional item (12) - 0% - Minority interest 53 45 20% - - Minority interest on exceptional item (8) - - - - NET PROFIT BEFORE EXCEPTIONAL ITEM 273 319 -30% - - - -<	TOTAL REVENUE	3,753	3,477	8%
Material & Power costs 1,327 1,229 8% Staff costs 832 742 12% Research & Development expenses* 266 255 4% Other expenses 342 413 -17% Manufacturing, staff & other expenses 2,766 2,639 5% EBITDA 987 839 18% Interest & Finance charges 42 19 123% Depreciation & Amortisation 396 345 15% Share of loss / (profit) in JV / Associate, net 107 9 100% PBT EFORE EXCEPTIONAL ITEM 442 466 -5% Exceptional item (70) - - - PBT 372 466 -20% - Taxes on exceptional item (12) - 0% - Minority interest 53 45 20% - - Minority interest on exceptional item (8) - - - - NET PROFIT BEFORE EXCEPTIONAL ITEM 273 319 -30% - - - -<	EXPENDITURE			
Staff costs 832 742 12% Research & Development expenses* 266 255 4% Other expenses 342 413 -17% Manufacturing, staff & other expenses 2,766 2,639 5% EBITDA 987 839 18% Interest & Finance charges 42 19 123% Depreciation & Amortisation 396 345 15% Share of loss / (profit) in JV / Associate, net 107 9 100% PBT BEFORE EXCEPTIONAL ITEM 442 466 -5% Exceptional item (70) - - NET PROFIT BEFORE MINORITY INTEREST 268 363 -26% Minority interest on exceptional item (12) - 0% Minority interest on exceptional item (8) - - NET PROFIT BEFORE EXCEPTIONAL ITEM 223 319 -30% EPS Rs. 1.9 2.7 - - Minority interest on exceptional item (8) - - - NET PROFIT BEFORE EXCEPTIONAL ITEM 273 319 -30		1,327	1,229	8%
Research & Development expenses* 266 255 4% Other expenses 342 413 -17% Manufacturing, staff & other expenses 2,766 2,639 5% EBITDA 987 839 18% Interest & Finance charges 42 19 123% Depreciation & Amortisation 396 345 15% Share of loss / (profit) in JV / Associate, net 107 9 100% PBT BEFORE EXCEPTIONAL ITEM 442 466 -5% Exceptional item (70) - - PBT 372 466 -20% Taxes 116 103 12% Taxes on exceptional item (12) - 0% NET PROFIT BEFORE MINORITY INTEREST 268 363 -26% Minority interest on exceptional item (8) - - NET PROFIT BEFORE EXCEPTIONAL ITEM 223 319 -30% EPS Rs. 1.9 2.7 - - NET PROFIT BEFORE EXCEPTIONAL ITE	Staff costs			12%
342 413 -17% Manufacturing, staff & other expenses 2,766 2,639 5% EBITDA 987 839 18% Interest & Finance charges 42 19 123% Depreciation & Amortisation 396 345 15% Share of loss / (profit) in JV / Associate, net 107 9 100% PBT BEFORE EXCEPTIONAL ITEM 442 466 -5% Exceptional item (70) - - PBT EXCEPTIONAL ITEM 442 466 -5% Exceptional item (70) - - - PBT EXCEPTIONAL ITEM 268 363 -26% Taxes 116 103 12% - NET PROFIT BEFORE MINORITY INTEREST 268 363 -26% Minority interest on exceptional item (8) - - NET PROFIT FOR THE PERIOD 223 319 -30% EPS Rs. 1.9 2.7 - - MET PR	Research & Development expenses*	266	255	4%
Manufacturing, staff & other expenses 2,766 2,639 5% EBITDA 987 839 18% Interest & Finance charges 42 19 123% Depreciation & Amortisation 396 345 15% Share of loss / (profit) in JV / Associate, net 107 9 100% PBT BEFORE EXCEPTIONAL ITEM 442 466 -5% Exceptional item (70) - - PBT 372 466 -20% Taxes 116 103 12% Taxes on exceptional item (12) - 0% NET PROFIT BEFORE MINORITY INTEREST 268 363 -26% Minority interest (8) - - Minority interest (8) - - NET PROFIT FOR THE PERIOD 223 319 -30% EXceptional item, net of taxes (50) - NET PROFIT BEFORE EXCEPTIONAL ITEM 273 319 -30% Exceptional item, net of taxes (50)		342	413	-17%
EBITDA 987 839 18% Interest & Finance charges 42 19 123% Depreciation & Amortisation 396 345 15% Share of loss / (profit) in JV / Associate, net 107 9 100% PBT BEFORE EXCEPTIONAL ITEM 442 466 -5% Exceptional item (70) - - PBT 372 466 -20% Taxes on exceptional item (12) - 0% NET PROFIT BEFORE MINORITY INTEREST 268 363 -26% Minority interest 53 45 20% Minority interest on exceptional item (8) - - NET PROFIT FOR THE PERIOD 223 319 -30% EXceptional item, net of taxes (50) - - NET PROFIT FOR THE PERIOD 223 319 -30% Exceptional item, net of taxes (50) - - NET PROFIT FOR THE PERIOD 223 319 -30% Exceptional item, net of taxes	· · · · · · · · · · · · · · · · · · ·	2,766	2,639	5%
Depreciation & Amortisation 396 345 15% Share of loss / (profit) in JV / Associate, net 107 9 100% PBT BEFORE EXCEPTIONAL ITEM 442 466 -5% Exceptional item (70) - - PBT 372 466 -20% Taxes 116 103 112% Taxes on exceptional item (12) - 0% NET PROFIT BEFORE MINORITY INTEREST 268 363 -26% Minority interest 53 45 20% Minority interest on exceptional item (8) - - NET PROFIT BEFORE EXCEPTIONAL ITEM 273 319 -30% EPS Rs. 1.9 2.7 - - NET PROFIT BEFORE EXCEPTIONAL ITEM 273 319 -14% Exceptional item, net of taxes (50) - - NET PROFIT FOR THE PERIOD 223 319 -30% # Licensing Income 22 21 - -				18%
Depreciation & Amortisation 396 345 15% Share of loss / (profit) in JV / Associate, net 107 9 100% PBT BEFORE EXCEPTIONAL ITEM 442 466 -5% Exceptional item (70) - - PBT 372 466 -20% Taxes 116 103 112% Taxes on exceptional item (12) - 0% NET PROFIT BEFORE MINORITY INTEREST 268 363 -26% Minority interest 53 45 20% Minority interest on exceptional item (8) - - NET PROFIT BEFORE EXCEPTIONAL ITEM 273 319 -30% EPS Rs. 1.9 2.7 - - NET PROFIT BEFORE EXCEPTIONAL ITEM 273 319 -14% Exceptional item, net of taxes (50) - - NET PROFIT FOR THE PERIOD 223 319 -30% # Licensing Income 22 21 - -	Interest & Finance charges	42	19	123%
PBT BEFORE EXCEPTIONAL ITEM 442 466 -5% Exceptional item (70) - 0% - - 0% - - 0% - 0% - 0% - 0% - 0% - 0% - 0% - 0% - 0% - 0% - 0% - 0% - 0% - 0% - - 0% - - 0% - - 0% - - - - - - - - - - - - <	Depreciation & Amortisation	396	345	15%
PBT BEFORE EXCEPTIONAL ITEM 442 466 -5% Exceptional item (70) - 0% - - 0% - - 0% - 0% - 0% - 0% - 0% - 0% - 0% - 0% - 0% - 0% - 0% - 0% - 0% - 0% - - 0% - - 0% - - 0% - - - - - - - - - - - - <		107	9	100%
PBT 372 466 -20% Taxes 116 103 12% Taxes on exceptional item (12) - 0% NET PROFIT BEFORE MINORITY INTEREST 268 363 -26% Minority interest 53 45 20% Minority interest on exceptional item (8) - - NET PROFIT FOR THE PERIOD 223 319 -30% EPS Rs. 1.9 2.7 - NET PROFIT BEFORE EXCEPTIONAL ITEM 273 319 -14% Exceptional item, net of taxes (50) - - NET PROFIT FOR THE PERIOD 223 319 -30% # Licensing Income 22 21 21		442	466	-5%
Taxes 116 103 12% Taxes on exceptional item (12) - 0% NET PROFIT BEFORE MINORITY INTEREST 268 363 -26% Minority interest 53 45 20% Minority interest on exceptional item (8) - - NET PROFIT FOR THE PERIOD 223 319 -30% EPS Rs. 1.9 2.7 - NET PROFIT BEFORE EXCEPTIONAL ITEM 273 319 -14% Exceptional item, net of taxes (50) - - NET PROFIT FOR THE PERIOD 223 319 -30% # Licensing Income 22 21 21	Exceptional item	(70)	-	-
Taxes on exceptional item (12) - 0% NET PROFIT BEFORE MINORITY INTEREST 268 363 -26% Minority interest 53 45 20% Minority interest on exceptional item (8) - - NET PROFIT FOR THE PERIOD 223 319 -30% EPS Rs. 1.9 2.7 - NET PROFIT BEFORE EXCEPTIONAL ITEM 273 319 -14% Exceptional item, net of taxes (50) - - NET PROFIT FOR THE PERIOD 223 319 -30% # Licensing Income 22 21 21	PBT	372	466	-20%
NET PROFIT BEFORE MINORITY INTEREST 268 363 26% Minority interest 53 45 20% Minority interest on exceptional item (8) - - NET PROFIT FOR THE PERIOD 223 319 -30% EPS Rs. 1.9 2.7 - NET PROFIT BEFORE EXCEPTIONAL ITEM 273 319 -14% Exceptional item, net of taxes (50) - - NET PROFIT FOR THE PERIOD 223 319 -30% Exceptional item, net of taxes (50) - - NET PROFIT FOR THE PERIOD 223 319 -30% # Licensing Income 22 21 21	Taxes	116	103	12%
Minority interest534520%Minority interest on exceptional item(8)NET PROFIT FOR THE PERIOD223319-30%EPS Rs.1.92.7-NET PROFIT BEFORE EXCEPTIONAL ITEM273319-14%Exceptional item, net of taxes(50)NET PROFIT FOR THE PERIOD223319-30%# Licensing Income222121	Taxes on exceptional item	(12)	-	0%
Minority interest on exceptional item(8)NET PROFIT FOR THE PERIOD223319-30%EPS Rs.1.92.7-NET PROFIT BEFORE EXCEPTIONAL ITEM273319-14%Exceptional item, net of taxes(50)NET PROFIT FOR THE PERIOD223319-30%# Licensing Income222121	NET PROFIT BEFORE MINORITY INTEREST	268	363	-26%
NET PROFIT FOR THE PERIOD 223 319 -30% EPS Rs. 1.9 2.7 - NET PROFIT BEFORE EXCEPTIONAL ITEM 273 319 -14% Exceptional item, net of taxes (50) - - NET PROFIT FOR THE PERIOD 223 319 -30% # Licensing Income 22 21 21	Minority interest	53	45	20%
EPS Rs.1.92.7NET PROFIT BEFORE EXCEPTIONAL ITEM273319-14%Exceptional item, net of taxes(50)NET PROFIT FOR THE PERIOD223319-30%# Licensing Income2221-	Minority interest on exceptional item	(8)	-	-
NET PROFIT BEFORE EXCEPTIONAL ITEM 273 319 -14% Exceptional item, net of taxes (50) - - NET PROFIT FOR THE PERIOD 223 319 -30% # Licensing Income 22 21 21	NET PROFIT FOR THE PERIOD	223	319	-30%
Exceptional item, net of taxes(50)-NET PROFIT FOR THE PERIOD223319-30%# Licensing Income22211	EPS Rs.	1.9	2.7	
NET PROFIT FOR THE PERIOD223319-30%# Licensing Income2221	NET PROFIT BEFORE EXCEPTIONAL ITEM	273	319	-14%
NET PROFIT FOR THE PERIOD223319-30%# Licensing Income2221	Exceptional item net of taxes	(50)	-	
	·		319	-30%
	# Licensing Income	22	21	
	* Gross Research & Development expenses	301	308	

BIOCON LIMITED (CONSOLIDATED)

Particulars	September 30, 2021	March 31, 2021
ASSETS		
Non-current assets		
(a) Property, plant and equipment	5,555	5,55
(b) Capital work-in-progress	2,788	2,25
(c) Right-of-use assets	151	15
(d) Goodwill	26	2
(e) Other intangible assets	640	62
(f) Intangible assets under development	594	54
(g) Investment in associates and a joint venture	77	18
(h) Financial assets		
Investments	342	56
Derivative assets	101	6
Other financial assets	101	20
	287	26
(i) Income tax asset, net		
(j) Deferred tax asset, net	292	30
(k) Other non-current assets	156	17
Non-current assets	11,116	10,92
Current assets		
(a) Inventories	2,273	1,86
(b) Financial assets		
Investments	1,406	1,20
Trade receivables	1,160	1,21
Cash and cash equivalents	663	95
Other bank balances	1,005	1,06
Derivative assets	101	8
Loans and advances	33	-
Other financial assets	660	79
(c) Other current assets	371	36
(c) Assets held for sale	5/1	5
Current assets	7,671	7,60
TOTAL - ASSETS	18,787	18.52
TOTAL - ASSETS	18,787	18,52
	18,787	18,52
EQUITY AND LIABILITIES	18,787	18,52
EQUITY AND LIABILITIES Equity		
EQUITY AND LIABILITIES Equity (a) Equity share capital	600	60
(b) Other equity	600 7,287	60 7,02
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company	600 7,287 7,888	60 7,02 7,62
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests	600 7,287 7,888 939	18,52 60 7,02 7,62 88
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company	600 7,287 7,888	60 7,02 7,62
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity	600 7,287 7,888 939	60 7,02 7,62 88
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities	600 7,287 7,888 939	60 7,02 7,62 88
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities	600 7,287 7,888 939 8,827	60 7,02 7,62 88 88 8,50
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities	600 7,287 7,888 939	60 7,02 7,62 88 88 8,50
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities	600 7,287 7,888 939 8,827	60 7,02 7,62 88 8,50 2,96
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Borrowings	600 7,287 7,888 939 8,827 3,028	60 7,02 7,62 88 8,50 2,96 11
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Borrowings Lease liabilities	600 7,287 7,888 939 8,827 3,028 103 47	60 7,02 7,62 88
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Borrowings Lease liabilities Derivative liabilities Other financial liabilities	600 7,287 7,888 939 8,827 3,028 103 47 1,503	60 7,02 7,62 88 8,50 2,96 11 6 1,50
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Borrowings Lease liabilities Derivative liabilities Other financial liabilities (b) Provisions	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Borrowings Lease liabilities Derivative liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Borrowings Lease liabilities Derivative liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net (d) Other non-current liabilities	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36 1,088	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3 1,02
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Borrowings Lease liabilities Derivative liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net (d) Other non-current liabilities	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3 1,02
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Borrowings Lease liabilities Derivative liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net (d) Other non-current liabilities Non-current liabilities	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36 1,088	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3 1,02
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Borrowings Lease liabilities Derivative liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net (d) Other non-current liabilities Non-current liabilities Current liabilities	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36 1,088	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3 1,02
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Derivative liabilities Derivative liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net (d) Other non-current liabilities Non-current liabilities Current liabilities (a) Financial liabilities	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36 1,088 5,920	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3 1,02 5,80
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Derivative liabilities Derivative liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net (d) Other non-current liabilities Non-current liabilities Current liabilities (a) Financial liabilities	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36 1,088 5,920	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3 1,02 5,80 1,39
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Derivative liabilities Derivative liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net (d) Other non-current liabilities Non-current liabilities Current liabilities (a) Financial liabilities Equitable (b) Equitable (c)	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36 1,088 5,920	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3 1,02 5,80 1,39
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Derivative liabilities Derivative liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net (d) Other non-current liabilities Non-current liabilities Current liabilities (a) Financial liabilities	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36 1,088 5,920	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3 1,02 5,80
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Borrowings Lease liabilities Other financial liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net (d) Other non-current liabilities Non-current liabilities Example 2 Non-current liabilities (a) Financial liabilities (a) Financial liabilities Borrowings Lease liabilities	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36 1,088 5,920	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3 1,02 5,80 1,39 1,51
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Derivative liabilities Derivative liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net (d) Other non-current liabilities Non-current liabilities Current liabilities (a) Financial liabilities Current liabilities (a) Financial liabilities Equitabilities Non-current liabilities Non-current liabilities Non-current liabilities Tarate payables	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36 1,088 5,920 1,594 1,594	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3 1,02 5,80 1,39 1,51 2
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Derivative liabilities Derivative liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net (d) Other non-current liabilities Non-current liabilities Current liabilities (a) Financial liabilities Current liabilities (a) Financial liabilities Equitabilities Non-current liabilities Derivative liabilities Derivative liabilities Derivative liabilities Derivative liabilities Derivative liabilities Derivative liabilities Derivative liabilities	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36 1,088 5,920 1,594 19 1,382 26	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3 1,02 5,80 1,39 1,51 2 38
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Borrowings Lease liabilities Derivative liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net (d) Other non-current liabilities Non-current liabilities Current liabilities Current liabilities Borrowings Lease liabilities Current liabilities Derivative liabilities Derivative liabilities Current liabilities Derivative liabilities Derivative liabilities Derivative liabilities Derivative liabilities (b) Provisions (c) Deferred financial liabilities Derivative liabilities Derivative liabilities Derivative liabilities Derivative liabilities (b) Provisions	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36 1,088 5,920 1,594 19 1,382 26 310 123	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3 1,02 5,80 1,51 2 38 1,51 2 38 1,51
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Borrowings Lease liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net (d) Other non-current liabilities Non-current liabilities Current liabilities (a) Financial liabilities Current liabilities Current liabilities Current liabilities Derivative liabilities Current liabilities (a) Financial liabilities Derivative liabilities (b) Provisions (c) Drevisions (c) Income tax liability, net	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36 1,088 5,920 1,594 19 1,382 26 310 123 174	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3 1,02 5,80 1,39 1,51 2 38 10 15
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Borrowings Lease liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net (d) Other non-current liabilities Non-current liabilities Current liabilities Borrowings Lease liabilities Current liabilities Derivative liabilities Derivative liabilities Current liabilities Derivative liabilities (a) Financial liabilities Derivative liabilities (b) Provisions (c) Income tax liability, net (d) Other current liabilities	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36 1,088 5,920 1,594 19 1,382 26 310 123	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3 1,02 5,80 1,51 2 38 1,51 2 38 1,51 2 38 1,51 2 38 1,51 2 5,80
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total Equity Non-current liabilities (a) Financial liabilities Borrowings Lease liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net (d) Other non-current liabilities Non-current liabilities Current liabilities Current liabilities Borrowings Lease liabilities Current liabilities Derivative liabilities (a) Financial liabilities Derivative liabilities (b) Provisions (c) Deferred tax liabilities Non-current liabilities Current liabilities Current liabilities (b) Provisions (c) Income tax liability, net (d) Other current liabilities (e) Liabilities classified as held for sale	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36 1,088 5,920 1,594 19 1,382 26 310 123 174 412	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3 1,02 5,80 1,51 2 38 1,51 2 38 10 1,55 2 38 10 58 4
EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Fotal Equity Non-current liabilities (a) Financial liabilities Borrowings Lease liabilities Other financial liabilities (b) Provisions (c) Deferred tax liability, net (d) Other non-current liabilities Non-current liabilities Current liabilities Current liabilities Current liabilities Derivative liabilities Current liabilities Derivative liabilities (a) Financial liabilities Derivative liabilities (b) Provisions (c) Deferred tax liabilities Current liabilities Current liabilities (b) Provisions (c) Income tax liability, net (d) Other current liabilities	600 7,287 7,888 939 8,827 3,028 103 47 1,503 116 36 1,088 5,920 1,594 19 1,382 26 310 123 174	60 7,02 7,62 88 8,50 2,96 11 6 1,50 10 3 1,02 5,80 1,51 2 38 1,51 2 38 1,51 2 38 1,51 2 38 1,51 2 5,80